Manuel Chiusa

Title: Manuel Chiusa: Innovator in Fibrotic Disease Research

Introduction

Manuel Chiusa is a notable inventor based in Nashville, TN (US). He has made significant contributions to the field of medical research, particularly in the area of fibrotic diseases. His innovative work has led to the development of a patent that addresses critical health issues related to collagen production.

Latest Patents

Manuel Chiusa holds a patent for "Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis." This patent discloses compositions and methods for inhibiting collagen production mediated by the Fused in Sarcoma (FUS) ribonucleoprotein. The invention highlights the C terminal domain of FUS, which contains a unique nuclear localization sequence (NLS) motif called PY-NLS that binds the nuclear import receptor transportin. The phosphorylation of FUS results in its association with transportin and nuclear translocation, leading to increased collagen production. The patent presents an isolated peptide with a transportin-binding moiety that inhibits FUS from binding transportin, linked to a membrane translocating motif. These compositions and methods can be utilized to inhibit FUS-mediated collagen production and treat fibrotic diseases involving collagen accumulation in kidneys and other organs.

Career Highlights

Throughout his career, Manuel Chiusa has worked with prestigious institutions, including Vanderbilt University and the United States Government as represented by the Department of Veterans Affairs. His research has focused on understanding and combating fibrotic diseases, making him a valuable asset in the medical research community.

Collaborations

Manuel has collaborated with esteemed colleagues such as Ambra A Pozzi and Jack Jacek Hawiger. These partnerships have furthered his research and contributed to advancements in the understanding of fibrotic diseases.

Conclusion

Manuel Chiusa's innovative work in the field of fibrotic disease research has led to significant advancements in medical science. His patent for FUS nuclear translocation inhibitors showcases his commitment to improving health outcomes for individuals affected by fibrotic diseases.